Q3 2023 Results

Company overview Financial review Conclusions Appendix References Remibrutinib demonstrated clinically meaningful and statistically significant benefit in Ph3 CSU trials Ph3 REMIX 1 & 2 studies Remibrutinib ~450 patients per study Screening R 2:1 Placebo Remibrutinib Follow up or extension Remibrutinib met ALL primary and secondary endpoints at 12 weeks Clinically meaningful and statistically significant reduction in urticaria activity Fast symptom improvement as early as 2 weeks¹ Well tolerated and favorable safety profile (incl. balanced liver function tests) Oral W-4 D 1 W 12 PE Double-blind treatment period PA W 24 Open-label treatment period W 52 W 56 All participants on a stable, locally label approved dose of a second generation H₁-AH ("background therapy") throughout the entire study Next steps Presentation at ACAAI 2023; final 52 week readout and filing expected in 2024 CSU Chronic spontaneous urticaria. PA Primary analysis. 1. As illustrated by a higher proportion of patients achieving UAS7≤6 at Week 2 in the REMIX-1 and REMIX-2 studies when treated with remibrutinib compared to placebo. 17 Investor Relations | Q3 2023 Results INNOVATION ✓ NOVARTIS | Reimagining Medicine

View entire presentation